Study of CP-461 in Patients With Advanced Renal Cell Cancer
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in
locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461
in this patient population.